Premium
A PHASE 2B OPEN‐LABEL SINGLE ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF HBI‐8000 (TUCIDINOSTAT) IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T‐CELL LYMPHOMA (PTCL)
Author(s) -
Kim W. S.,
Rai S.,
Ando K.,
Choi I.,
Izutsu K.,
Tsukamoto N.,
Yokoyama M.,
Tsukasaki K.,
Kuroda J.,
Ando J.,
Hidaka M.,
Koh Y.,
Shibayama H.,
Uchida T.,
Yang D. H.,
Ishitsuka K.,
Ishizawa K.,
Kim J. S.,
Lee H. G.,
Minami H.,
Eom H. S.,
Nagai H.,
Kurosawa M.,
Lee J. H.,
Lee W. S.,
Shindo T.,
Yoon D. H.,
Yoshida S.,
Gillings M.,
Onogi H.,
Tobinai K.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.121_2880
Subject(s) - medicine , common terminology criteria for adverse events , clinical endpoint , refractory (planetary science) , adverse effect , peripheral t cell lymphoma , lymphoma , surrogate endpoint , surgery , gastroenterology , oncology , clinical trial , t cell , immunology , immune system , astrobiology , physics